- Home
- HNST vs ETNB Comparison
HNST vs ETNB Comparison
Compare HNST & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNST
- ETNB
- Stock Information
- Founded
- HNST 2012
- ETNB 2018
- Country
- HNST United States
- ETNB United States
- Employees
- HNST N/A
- ETNB N/A
- Industry
- HNST Catalog/Specialty Distribution
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- HNST Consumer Discretionary
- ETNB Health Care
- Exchange
- HNST Nasdaq
- ETNB Nasdaq
- Market Cap
- HNST 647.2M
- ETNB 773.7M
- IPO Year
- HNST 2021
- ETNB 2019
- Fundamental
- Price
- HNST $5.73
- ETNB $11.06
- Analyst Decision
- HNST Buy
- ETNB Strong Buy
- Analyst Count
- HNST 5
- ETNB 9
- Target Price
- HNST $6.90
- ETNB $31.43
- AVG Volume (30 Days)
- HNST 1.9M
- ETNB 3.9M
- Earning Date
- HNST 02-26-2025
- ETNB 02-27-2025
- Dividend Yield
- HNST N/A
- ETNB N/A
- EPS Growth
- HNST N/A
- ETNB N/A
- EPS
- HNST N/A
- ETNB N/A
- Revenue
- HNST $368,767,000.00
- ETNB N/A
- Revenue This Year
- HNST $11.09
- ETNB N/A
- Revenue Next Year
- HNST $5.81
- ETNB N/A
- P/E Ratio
- HNST N/A
- ETNB N/A
- Revenue Growth
- HNST 9.77
- ETNB N/A
- 52 Week Low
- HNST $2.40
- ETNB $5.99
- 52 Week High
- HNST $8.97
- ETNB $16.63
- Technical
- Relative Strength Index (RSI)
- HNST 38.80
- ETNB 63.82
- Support Level
- HNST $5.86
- ETNB $10.43
- Resistance Level
- HNST $6.46
- ETNB $11.31
- Average True Range (ATR)
- HNST 0.29
- ETNB 0.65
- MACD
- HNST -0.01
- ETNB -0.02
- Stochastic Oscillator
- HNST 2.01
- ETNB 70.90
About HNST The Honest Company Inc.
The Honest Co Inc is a digitally-native consumer products company to makes purpose-driven consumer products designed for all people. It is an omnichannel brand, ensuring its products are available wherever its consumers shop through the company's Retail and Digital channels. It has three product categories namely; Diapers and Wipes, Skin and Personal Care, and Household and Wellness, out of which the majority of its revenue is generated from the sale of diapers and wipes. The company operates only in the United States.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).